A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

Keiichiro Ishibashi, Kensuke Kumamoto, Keiji Koda, Hiroyuki Kato, Genichi Nishimura, Kazuhiko Yoshimatsu, Hajime Yokomizo, Shinji Ooki, Soichi Tanaka, Michio Asano, Masaru Yokoyama, Tomoyuki Kawada (+1 others)
2016 Annals of Cancer Research and Therapy  
This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.
doi:10.4993/acrt.24.17 fatcat:ziikos6cnfemjhybgoo6n7cnc4